Background: Metabolic surgery (MS) is the most durable treatment of obesity and can treat obstructive sleep apnea (OSA).
Objectives: To compare trajectories of positive airway pressure (PAP) device use between individuals who had MS and similar individuals who did not have MS (non-MS).
Setting: Merative MarketScan Research Databases - a US-based commercial claims database.
Methods: Those who underwent MS were matched 1:1 with nonoperative controls on baseline demographic and health characteristics. PAP use trajectories were examined in the 3years after the index dates and stratified by baseline PAP use.
Results: A total of 8772 adults who had MS were matched with 8772 adults who did not have MS; in both groups, 17.3% had baseline PAP claims. Among individuals who had baseline PAP claims, those who had MS had significantly higher rates of PAP use cessation (58.9% versus 27.1%; P value < .01). Among individuals who were not using a PAP at baseline, PAP initiation was higher among those who did not have MS than those who had MS (10.8% versus 2.6%; P value < .01).
Conclusions: MS was associated with discontinuation of PAP use and decreased initiation of PAP use among individuals who were not using these devices, suggesting that MS leads to symptomatic and preventive treatment for OSA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.soard.2025.01.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal changes in positive airway pressure device use after metabolic surgery: a 3-year matched cohort study of National Claims Data.
Surg Obes Relat Dis
February 2025
Metamor Institute, Pennington Biomedical Research Center at Louisiana State University, Baton Rouge, Louisiana; Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, Louisiana. Electronic address:
Background: Metabolic surgery (MS) is the most durable treatment of obesity and can treat obstructive sleep apnea (OSA).
Objectives: To compare trajectories of positive airway pressure (PAP) device use between individuals who had MS and similar individuals who did not have MS (non-MS).
Setting: Merative MarketScan Research Databases - a US-based commercial claims database.
Hemodynamic effect of outpatient levosimendan infusion assessed daily using the CardioMEMS invasive remote monitoring system.
Rev Port Cardiol
March 2025
Department of Cardiology, Hospital de Santa Marta, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.
Introduction And Objectives: Levosimendan infusion in the outpatient setting improves the clinical status of heart failure (HF) patients, although its hemodynamic effects are not entirely known. Remote monitoring using the CardioMEMS system enables daily assessment of pulmonary artery pressure (PAP) and estimation of cardiac output (CO). We aimed to assess the hemodynamic effects of outpatient levosimendan infusion using CardioMEMS.
View Article and Find Full Text PDFHeart Rate response and cardiovascular risk during OSA: an easy biomarker derived from pulse oximetry.
Eur Respir J
February 2025
Department of Respiratory and Sleep Medicine, Angers University Hospital, Angers, France
Background: Sleep apnoea specific heart rate response (ΔHR) has been identified as a promising biomarker for stratifying cardiovascular (CV) risk, and predicting positive airway pressure (PAP) benefit in obstructive sleep apnoea (OSA). However, the need for prior manual scoring of respiratory events potentially limits the accessibility and reproducibility of ΔHR. We aimed to evaluate the association of pulse rate response to oxygen desaturations automatically derived from pulse oximetry (ΔHR) with CV risk in OSA.
View Article and Find Full Text PDFThe healthcare burden of pulmonary alveolar proteinosis (PAP).
Orphanet J Rare Dis
February 2025
UCLA Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California Los Angeles, 650 Charles E. Young Drive South, 43-229 CHS, Los Angeles, CA, 90095-1690, USA.
Introduction: Pulmonary alveolar proteinosis (PAP) is a rare lung syndrome characterized by the accumulation of surfactant in the alveoli. Using a longitudinal claims database, we compared measures of clinical and economic burden between a sample of diagnosed PAP patients and non-PAP matched controls.
Methods: PAP patients were identified leveraging IPM.
Cognition and obstructive sleep apnea in Parkinson's disease: randomized controlled trial of positive airway pressure (COPE-PAP trial).
Sleep
February 2025
Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Study Objectives: This randomized controlled trial assessed the effects of positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA) on cognition in patients with Parkinson's disease (PD).
Methods: Individuals with PD with Montreal Cognitive Assessment (MoCA) < 27 and OSA were randomized to PAP or nasal dilator strips (placebo) for 6 months. The primary outcome was the change in MoCA from baseline to 6 months compared by t-test between groups by intention to treat (ITT).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!